PKM1 Antibody - BSA Free

Western Blot: PKM1 AntibodyBSA Free [NBP2-14833]

Western Blot: PKM1 Antibody [NBP2-14833] - Detection of PKM1 on HEK293T and U-87 cells. Lane 1: HEK293T cells (major isoform is PKM2, human). Lane 2: HEK293T cells with plasmid overexpressing mouse PKM1. Lane 3: HEK293T cells with plasmid overexpressing mouse PKM2. Lane 4: U-87 cells with control shRNA (major isoform is PKM2, human). Lane 5: U-87 cells with PTB/A1/A2 shRNAs (major isoform is PKM1, human). Photo courtesy of product review by verified customer.

Western Blot: PKM1 AntibodyBSA Free [NBP2-14833]

PKM1-Antibody-Western-Blot-NBP2-14833-img0006.jpg

Western Blot: PKM1 AntibodyBSA Free [NBP2-14833]

PKM1-Antibody-Western-Blot-NBP2-14833-img0007.jpg

Simple Western: PKM1 AntibodyBSA Free [NBP2-14833]

Simple Western: PKM1 Antibody [NBP2-14833] - Simple Western lane view shows a specific band for PKM1 in 0.5 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.

Immunohistochemistry-Paraffin: PKM1 Antibody - BSA Free [NBP2-14833] -

Immunohistochemistry-Paraffin: PKM1 Antibody - BSA Free [NBP2-14833] - Expression of PKM1 & PKM2 in clinical colorectal cancer samples.(a) The protein expression of PKM1 & PKM2 in clinical specimens of cancer tumor (T) & the adjacent normal tissues (N) is shown. PKM1 & PKM2 were detected by Western blotting in under the same experimental conditions at the same time. The full-length blots are presented in Supplementary Figure S3b. (b–d) Immunohistochemical staining of normal colon tissue adjacent to tumor tissue of case 10. Results of H&E staining (b), staining with anti-PKM1 antibody (c), & staining with anti-PKM2 (d) are shown. The boxed regions in “c” & “d” are enlarged in the images below. (e–h) Immunohistochemical staining of clinical colorectal cancer tissue specimen of representative case 3. H&E-stained section with normal tissue (upper right corner) neighboring the tumor area in the section is shown (e), along with the same section stained with anti-PKM2 antibody (f). Enlarged views of boxed areas in “f” show normal colorectal crypt in mucosa (g) & tumor area (h) stained with anti-PKM2 antibody. Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep08647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] -

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] - (a) Luciferase activities after co-transfection of DLD-1 cells w/ control or miR-124 (wild-type or mutant-type) pMIR vectors having predictive miR-124 binding site in 3′UTR of PTB1. Upper panel region of 3′-UTR of human PTB1 mRNA complementary to mature miR-124. Box indicates predicted binding sites for miR-124. (b) Same as “a” except miR-133b used. (c) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, NB9 or IMR-32 cells w/ miR-124 (10, 20 or 40 nM). (d) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, RD or KYM-1 cells w/ miR-133b (10, 20 nM). (e) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, NB-9 or RD cells w/ siR-PTB1 (2, 5 nM). (f) Effect of combined treatment of DLD-1 cells w/ antagomiR-124 & miR-124 or antagomiR-133b & miR-133b. DLD-1 cells transfected w/ non-specific control, miR-124/miR-133b (10 nM), miR-124/miR-133b (10 nM) + antagomiR-124/antagomiR-133b (5 nM) or miR-124/miR-133b (10 nM) + antagomiR-124/antagomiR-133b (10 nM). Expression level of PTB1 assessed at 48 h after transfection. The full-length blots are presented in Supplementary Figure S3a. (g) IF of PKM1 (upper panels) & PKM2 (lower panels) at 48 h after transfection of DLD-1 cells w/ miR-124 (20 nM) or miR-133b (20 nM). Left panels, treatment w/ control miRNA; middle panels, treatment w/ miR-124; right panels, treatment w/ miR-133b. PKM1 or PKM2 is stained red, & nuclei are stained blue. (h) Lactate production measured at 48 h after transfection of DLD-1 cells w/ miR-124 (20 nM), miR-133b (20 nM) or siR-PTB1 (5 nM). Results are presented as mean± SD (* P < 0.05; ** P < 0.01; *** P < 0.001; N.S., not statistically significant). Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep08647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Immunocytochemistry/ Immunofluorescence: PKM1 Antibody - BSA Free [NBP2-14833] -

Immunocytochemistry/ Immunofluorescence: PKM1 Antibody - BSA Free [NBP2-14833] - (a) Luciferase activities after co-transfection of DLD-1 cells w/ control or miR-124 (wild-type or mutant-type) pMIR vectors having predictive miR-124 binding site in 3′UTR of PTB1. Upper panel region of 3′-UTR of human PTB1 mRNA complementary to mature miR-124. Box indicates predicted binding sites for miR-124. (b) Same as “a” except miR-133b used. (c) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, NB9 or IMR-32 cells w/ miR-124 (10, 20 or 40 nM). (d) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, RD or KYM-1 cells w/ miR-133b (10, 20 nM). (e) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, NB-9 or RD cells w/ siR-PTB1 (2, 5 nM). (f) Effect of combined treatment of DLD-1 cells w/ antagomiR-124 & miR-124 or antagomiR-133b & miR-133b. DLD-1 cells transfected w/ non-specific control, miR-124/miR-133b (10 nM), miR-124/miR-133b (10 nM) + antagomiR-124/antagomiR-133b (5 nM) or miR-124/miR-133b (10 nM) + antagomiR-124/antagomiR-133b (10 nM). Expression level of PTB1 assessed at 48 h after transfection. The full-length blots are presented in Supplementary Figure S3a. (g) IF of PKM1 (upper panels) & PKM2 (lower panels) at 48 h after transfection of DLD-1 cells w/ miR-124 (20 nM) or miR-133b (20 nM). Left panels, treatment w/ control miRNA; middle panels, treatment w/ miR-124; right panels, treatment w/ miR-133b. PKM1 or PKM2 is stained red, & nuclei are stained blue. (h) Lactate production measured at 48 h after transfection of DLD-1 cells w/ miR-124 (20 nM), miR-133b (20 nM) or siR-PTB1 (5 nM). Results are presented as mean± SD (* P < 0.05; ** P < 0.01; *** P < 0.001; N.S., not statistically significant). Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep08647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] -

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] - (a) Luciferase activities after co-transfection of DLD-1 cells w/ control or miR-124 (wild-type or mutant-type) pMIR vectors having predictive miR-124 binding site in 3′UTR of PTB1. Upper panel region of 3′-UTR of human PTB1 mRNA complementary to mature miR-124. Box indicates predicted binding sites for miR-124. (b) Same as “a” except miR-133b used. (c) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, NB9 or IMR-32 cells w/ miR-124 (10, 20 or 40 nM). (d) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, RD or KYM-1 cells w/ miR-133b (10, 20 nM). (e) Expression of PTB1, PKM1, & PKM2 proteins at 72 h after transfection of DLD-1, NB-9 or RD cells w/ siR-PTB1 (2, 5 nM). (f) Effect of combined treatment of DLD-1 cells w/ antagomiR-124 & miR-124 or antagomiR-133b & miR-133b. DLD-1 cells transfected w/ non-specific control, miR-124/miR-133b (10 nM), miR-124/miR-133b (10 nM) + antagomiR-124/antagomiR-133b (5 nM) or miR-124/miR-133b (10 nM) + antagomiR-124/antagomiR-133b (10 nM). Expression level of PTB1 assessed at 48 h after transfection. The full-length blots are presented in Supplementary Figure S3a. (g) IF of PKM1 (upper panels) & PKM2 (lower panels) at 48 h after transfection of DLD-1 cells w/ miR-124 (20 nM) or miR-133b (20 nM). Left panels, treatment w/ control miRNA; middle panels, treatment w/ miR-124; right panels, treatment w/ miR-133b. PKM1 or PKM2 is stained red, & nuclei are stained blue. (h) Lactate production measured at 48 h after transfection of DLD-1 cells w/ miR-124 (20 nM), miR-133b (20 nM) or siR-PTB1 (5 nM). Results are presented as mean± SD (* P < 0.05; ** P < 0.01; *** P < 0.001; N.S., not statistically significant). Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep08647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] -

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] - Expression of PKM1 & PKM2 in clinical colorectal cancer samples.(a) The protein expression of PKM1 & PKM2 in clinical specimens of cancer tumor (T) & the adjacent normal tissues (N) is shown. PKM1 & PKM2 were detected by Western blotting in under the same experimental conditions at the same time. The full-length blots are presented in Supplementary Figure S3b. (b–d) Immunohistochemical staining of normal colon tissue adjacent to tumor tissue of case 10. Results of H&E staining (b), staining with anti-PKM1 antibody (c), & staining with anti-PKM2 (d) are shown. The boxed regions in “c” & “d” are enlarged in the images below. (e–h) Immunohistochemical staining of clinical colorectal cancer tissue specimen of representative case 3. H&E-stained section with normal tissue (upper right corner) neighboring the tumor area in the section is shown (e), along with the same section stained with anti-PKM2 antibody (f). Enlarged views of boxed areas in “f” show normal colorectal crypt in mucosa (g) & tumor area (h) stained with anti-PKM2 antibody. Image collected & cropped by CiteAb from the following publication (https://www.nature.com/articles/srep08647), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] -

Western Blot: PKM1 Antibody - BSA Free [NBP2-14833] - Characterization of NOX4 & PKM2 in human RCC tumors & adjacent tissue. a Mitochondrial fractions were prepared from human tumors (T) or uninvolved adjacent tissue (N). NOX4 expression was examined by western blot analysis. Prohibitin was probed as a mitochondrial marker & loading control. b Quantitation of NOX4 distribution in the mitochondrial fraction from a. The results are expressed as the means using one-way ANOVA with Tukey’s post hoc test where ± S.E.M. *p < 0.05 compared to normal (N). c Mitochondria fractions were prepared from RCC tumors & NADPH-dependent superoxide generation was examined in the presence (+) or absence (−) of ATP. The results are from eight tumors & are expressed as the means using one-way ANOVA with Tukey’s post hoc test where ±S.E.M. **p < 0.01 is compared to without (−) ATP. d PKM2 & PKM1 expression was examined by western blot analysis in lysates prepared from human tumors (T) or uninvolved adjacent tissue (N) from the same patient. Actin as loading control Image collected & cropped by CiteAb from the following publication (https://pubmed.ncbi.nlm.nih.gov/29051480), licensed under a CC-BY license. Not internally tested by Novus Biologicals.